Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL10030513 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL18402620 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-12251402-B2 | Mesenchymal stem cells with enhanced immunosuppressive capability | ESCAPE THERAPEUTICS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240301054-A1 | TIM-3 INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-20240301053-A1 | COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2008101448-A2 | METHOD OF MANUFACTURING 1-(2-DEOXY-ALPHA-D-ERYTHRO-PENTOFURANOSYL)-5-AZACYTOSINE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101448-A2 | METHOD OF MANUFACTURING 1-(2-DEOXY-ALPHA-D-ERYTHRO-PENTOFURANOSYL)-5-AZACYTOSINE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2008-08-28 | — | — | WO | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008083634-A1 | 1-(2-DEOXY-ALPHA-D-ERYTHRO-PENTOFURANOSYL)-5-AZACYTOSINE FOR USE AS DRUG | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008083634-A1 | 1-(2-DEOXY-ALPHA-D-ERYTHRO-PENTOFURANOSYL)-5-AZACYTOSINE FOR USE AS DRUG | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2008-07-17 | — | — | WO | disclosed |
| US-20070117776-A1 | Low Dose Therapy Of DNA Methylation Inhibitors | SUPERGEN, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | disclosed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | DNMT1 2168/4885ADRB1 4416/4885LMNA 4056/4885 |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | DNMT1 2907/4885ADRB1 4482/4885LMNA 3085/4885 |
| US-20240301054-A1 | TIM-3 INHIBITORS AND USES THEREOF | HAVCR2, CD58, LGALS3 | DNMT1 2930/4885ADRB1 3784/4885LMNA 2642/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | DNMT1 3525/4885ADRB1 4535/4885LMNA 2907/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | DNMT1 1975/4885ADRB1 4096/4885LMNA 2705/4885 |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | DNMT1 111/4885ADRB1 2700/4885LMNA 835/4885 |
| US-12251402-B2 | Mesenchymal stem cells with enhanced immunosuppressive capability | HLA-C, HLA-B, HLA-DRB1 | DNMT1 7/4885ADRB1 2511/4885LMNA 3899/4885 |
| US-20240301053-A1 | COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS | HAVCR2, BCL3, BIRC3 | DNMT1 2240/4885ADRB1 3969/4885LMNA 2056/4885 |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | RRM2, RRM2B, RRM1 | DNMT1 513/4885ADRB1 2260/4885LMNA 3520/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | DNMT1 2907/4885ADRB1 4482/4885LMNA 3085/4885 |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | DCTD, DNMT3A, HDAC5 | DNMT1 5/4885ADRB1 4614/4885LMNA 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.